Lymph Node Cytology

  • Von G. Samedi
  • Qian-Yun ZhangEmail author
Part of the Atlas of Anatomic Pathology book series (AAP)


Lymph nodes are among the most commonly sampled organs. The common causes of lymphadenopathy include metastatic cancers, reactive hyperplasia due to various stimuli, infections, and lymphomas. Fine-needle aspiration (FNA) of a lymph node is a safe, relatively simple, and effective modality in the evaluation of lymphadenopathy. Diff-Quik stain offers rapid provisional assessment and can guide the further workup for the patient. Diff-Quik stain also provides information on cytoplasm and extracellular matrix. Papanicolaou stain reveals nuclear details. Cell block allows histologic sections and immunohistochemical studies. FNA can provide samples for ancillary studies such as flow cytometric analysis and cytogenetic and molecular studies. Ancillary studies are complementary to morphology and can further improve the diagnostic accuracy. This chapter summarizes the cytological features of various lymph node lesions and defines the roles of ancillary studies in the diagnosis and prognosis.


Follicular hyperplasia Lymphadenitis Lymphadenopathy Lymphoma 


  1. 1.
    Schafernak KT, Kluskens LF, Ariga R, Reddy VB, Gattuso P. Fine-needle aspiration of superficial and deeply seated lymph nodes on patients with and without a history of malignancy: review of 439 cases. Diagn Cytopathol. 2003;29:315–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Nasuti JF, Mehrotra R, Gupta PK. Diagnostic value of fine-needle aspiration in supraclavicular lymphadenopathy: a study of 106 patients and review of literature. Diagn Cytopathol. 2001;25:351–5.CrossRefPubMedGoogle Scholar
  3. 3.
    Glant MD. Cytopathology of lymph nodes in nonspecific reactive hyperplasia. Prognostication and differential diagnoses. Am J Clin Pathol. 1997;108(4 Suppl 1):S31–55.PubMedGoogle Scholar
  4. 4.
    O’Dowd GJ, Frable WJ, Behm FG. Fine needle aspiration cytology of benign lymph node hyperplasias. Diagnostic significance of lymphohistiocytic aggregates. Acta Cytol. 1985;29:554–8.PubMedGoogle Scholar
  5. 5.
    Pilotti S, Di Palma S, Alasio L, Bartoli C, Rilke F. Diagnostic assessment of enlarged superficial lymph nodes by fine needle aspiration. Acta Cytol. 1993;37:853–66.PubMedGoogle Scholar
  6. 6.
    Schwarz R, Chan NH, MacFarlane JK. Fine needle aspiration cytology in the evaluation of head and neck masses. Am J Surg. 1990;159:482–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Zhou J, Li F, Meng L, Hao F, Liu X, Zhao C, et al. Fine needle aspiration cytology for lymph nodes: a three-year study. Br J Biomed Sci. 2016;73:28–31.CrossRefPubMedGoogle Scholar
  8. 8.
    Ramzy I, Rone R, Schultenover SJ, Buhaug J. Lymph node aspiration biopsy. Diagnostic reliability and limitations—an analysis of 350 cases. Diagn Cytopathol. 1985;1:39–45.CrossRefPubMedGoogle Scholar
  9. 9.
    Hyun SJ, Kim EK, Yoon JH, Moon HJ, Kim MJ. Adding MRI to ultrasound and ultrasound-guided fine-needle aspiration reduces the false-negative rate of axillary lymph node metastasis diagnosis in breast cancer patients. Clin Radiol. 2015;70:716–22.CrossRefPubMedGoogle Scholar
  10. 10.
    Basler GC, Fader DJ, Yahanda A, Sondak VK, Johnson TM. The utility of fine needle aspiration in the diagnosis of melanoma metastatic to lymph nodes. J Am Acad Dermatol. 1997;36:403–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Wang H, Liang J, Yong WH, Sullivan P. Metastatic pituitary carcinoma to cervical lymph node: diagnosis by fine needle aspiration and review of the literature. Acta Cytol. 2017;61:242–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Stewart CJ, Duncan JA, Farquharson M, Richmond J. Fine needle aspiration cytology diagnosis of malignant lymphoma and reactive lymphoid hyperplasia. J Clin Pathol. 1998;51:197–203.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Das DK. Value and limitations of fine-needle aspiration cytology in diagnosis and classification of lymphomas: a review. Diagn Cytopathol. 1999;21:240–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Katz RL. Cytologic diagnosis of leukemia and lymphoma. Values and limitations. Clin Lab Med. 1991;11:469–99.PubMedCrossRefGoogle Scholar
  15. 15.
    Katz RL, Caraway NP. FNA lymphoproliferative diseases: myths and legends. Diagn Cytopathol. 1995;12:99–100.CrossRefPubMedGoogle Scholar
  16. 16.
    Sneige N. Diagnosis of lymphoma and reactive lymphoid hyperplasia by immunocytochemical analysis of fine-needle aspiration biopsy. Diagn Cytopathol. 1990;6:39–43.CrossRefPubMedGoogle Scholar
  17. 17.
    Paull G, Mosunjac M. Fine-needle aspiration biopsy and intraoperative cytologic smear findings in a case of benign mesothelial-cell inclusions involving a lymph node: case report and review of the literature. Diagn Cytopathol. 2003;29:163–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Gallan AJ, Antic T. Benign müllerian glandular inclusions in men undergoing pelvic lymph node dissection. Hum Pathol. 2016;57:136–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.CrossRefGoogle Scholar
  20. 20.
    Stein H, Delsol G, Pileri SA, Poppema S, Jaffe ES. Classical Hodgkin lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008. p. 326–9.Google Scholar
  21. 21.
    The Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood. 1997;89:3909–18.Google Scholar
  22. 22.
    Dal Bo M, Bulian P, Bomben R, Zucchetto A, Rossi FM, Pozzo F, et al. CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. Leukemia. 2016;30:2011–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Gooden CE, Jones P, Bates R, Shallenberger WM, Surti U, Swerdlow SH, Roth CG. CD49d shows superior performance characteristics for flow cytometric prognostic testing in chronic lymphocytic leukemia/small lymphocytic lymphoma. Cytometry B Clin Cytom. 2018;94(1):129–35. Scholar
  24. 24.
    Strati P, Parikh SA, Chaffee KG, Achenbach SJ, Slager SL, Call TG, et al. CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia. Br J Haematol. 2017;178:99–105.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, et al. Non-Hodgkin’s lymphomas, version 3.2012. J Natl Compr Canc Netw. 2012;10:1487–98.CrossRefPubMedGoogle Scholar
  26. 26.
    Chen R, Sanchez J, Rosen ST. Clinical management updates in mantle cell lymphoma. Oncology (Williston Park). 2016;30:353–60.Google Scholar
  27. 27.
    Hashmi AA, Hussain ZF, Faridi N, Khurshid A. Distribution of Ki67 proliferative indices among WHO subtypes of non-Hodgkin’s lymphoma: association with other clinical parameters. Asian Pac J Cancer Prev. 2014;15:8759–63.CrossRefPubMedGoogle Scholar
  28. 28.
    Katzenberger T, Petzoldt C, Höller S, Mäder U, Kalla J, Adam P, et al. The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood. 2006;107:3407.CrossRefPubMedGoogle Scholar
  29. 29.
    Hsi ED, Jung SH, Lai R, Johnson JL, Cook JR, Jones D, et al. Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. Leuk Lymphoma. 2008;49:2081–90.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol. 1998;9:717–20.CrossRefPubMedGoogle Scholar
  31. 31.
    Koch K, Hoster E, Ziepert M, Unterhalt M, Ott G, Rosenwald A, et al. Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL. Ann Oncol. 2016;27:1323–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Mercadal S, Pomares H, Sancho JM, Climent F, García O, Encuentra M, et al. Clinico-biological features, treatment and survival of 457 patients with histological Grades 3A and 1-2 follicular lymphoma mostly treated with immunochemotherapy. Br J Haematol. 2016;172:470–3.CrossRefPubMedGoogle Scholar
  33. 33.
    Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC, et al. German High-Grade Non-Hodgkin Lymphoma Study Group. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013;121:2253–63.CrossRefPubMedGoogle Scholar
  34. 34.
    Klopčič U, Lavrenčak J, Gašljević G, Bračko M, Pohar-Marinšek Ž, Kloboves-Prevodnik V. Grading of follicular lymphoma in cytological samples. Cytopathology. 2016;27:390–7.CrossRefPubMedGoogle Scholar
  35. 35.
    Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–82.CrossRefPubMedGoogle Scholar
  36. 36.
    Horn H, Schmelter C, Leich E, Salaverria I, Katzenberger T, Ott MM, et al. Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles. Haematologica. 2011;96:1327–34.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Snuderl M, Kolman OK, Chen YB, Hsu JJ, Ackerman AM, Dal Cin P, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol. 2010;34:327–40.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    McKenna RW, Kyle RA, Kuehl WM, Grogan TM, Harris NL, Coupland RW. Plasma cell neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008. p. 200–13.Google Scholar
  39. 39.
    Cazals-Hatem D, Lepage E, Brice P, Ferrant A, d’Agay MF, Baumelou E, et al. Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA (“Groupe d’Etude des Lymphomes de l’Adulte”) study. Am J Surg Pathol. 1996;20:877–88.CrossRefPubMedGoogle Scholar
  40. 40.
    Barth TF, Leithäuser F, Joos S, Bentz M, Möller P. Mediastinal (thymic) large B-cell lymphoma: where do we stand? Lancet Oncol. 2002;3:229–34.CrossRefPubMedGoogle Scholar
  41. 41.
    Poppema S, Delsol G, Pileri SA, Stein H. Nodular lymphocyte predominant Hodgkin lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008. p. 323–5.Google Scholar
  42. 42.
    Delsol G. [The 2008 WHO lymphoma classification]. Ann Pathol. 2008;28 Spec No 1:S20–4.Google Scholar
  43. 43.
    Pileri SA, Orazi A, Falini B. Myeloid sarcoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008. p. 140–1.Google Scholar
  44. 44.
    Almagro UA, Choi H, Rouse TM. Hemangioma in a lymph node. Arch Pathol Lab Med. 1985;109:576–8.PubMedGoogle Scholar
  45. 45.
    Reich RF, Moss S, Freedman PD. Intranodal hemangioma of the oral soft tissues: a case report of a rare entity with review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000;90:71–3.CrossRefPubMedGoogle Scholar
  46. 46.
    Kasznica J, Sideli RV, Collins MH. Lymph node hemangioma. Arch Pathol Lab Med. 1989;113:804–7.PubMedGoogle Scholar
  47. 47.
    Wakely PE Jr, Frable WJ, Kneisl JS. Aspiration cytopathology of epithelioid angiosarcoma. Cancer. 2000;90:245–51.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of PathologyUniversity of New Mexico HospitalAlbuquerqueUSA

Personalised recommendations